POLAR Registry (Promus eluting stent registry in Latin America): 1 year Follow-up Results

Abstract

Background: Drug-eluting stents have been used in patients to achieve success with low clinical and angiographic restenosis since 2002. Since late thrombosis adverse events were associated with first generation everolimus- and paclitaxel-eluting stents, second-generation everolimus and zotarolimus-eluting stents were developed. Methods: The POLAR registry was a prospective, non-randomised, multicentre study, which included 988 patients and 1,362 lesions that were treated with the Promus® everolimus-eluting stent. To represent clinical practice, almost all patient and lesion subtypes were included in this registry. Clinical follow-ups were performed at one, six, 12, and 24 months after the procedure. Results: Most of the patients were male (69.8%), with a mean age of 64.9 ± 9.4 years, 35.2% were diabetics, and 55% had been treated for acute coronary syndrome. The mean vessel diameter of the patients was 2.95 ± 0.43 mm, and their lesions extended 20.5 ± 5.6 mm. A total of 1.14 ± 0.38 stents were implanted per patient, with a procedural success rate of 96.6%. Major adverse cardiac events occurred in 4.5% of patients, and stent thrombosis was observed in five patients (0.5%) after 12 months of clinical follow-up. Conclusions: The present registry suggests that everolimuseluting stents are safe and effective in daily clinical practice, with a low rate of major adverse cardiac events after 12 months of follow-up.